UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
October 25, 2006
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
750
Lexington Avenue, 20th
Floor
New
York, New York 10022
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F x
Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): o
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
XTL
BIOPHARMACEUTICALS LTD. AGM POSTPONED UNTIL NOVEMBER 1,
2006
NEW
YORK, NEW YORK, October
25,
2006
- XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announces
today
that its Annual General Meeting (“AGM”) was postponed for one week in accordance
with its articles of association due to the absence of a quorum. The postponed
AGM will take place at the
Company, Building 3, Kiryat Weizmann Science Park, Rehovot, PO Box 370, Israel
76100 at 4:00 p.m. on
November 1, 2006.
Any
proxy
votes received at any time up to 48 hours prior to the postponed AGM will be
included in the total votes counted for the AGM. Those shareholders who have
a
valid “proof of ownership” in Israel or a letter of representation from
Computershare, the Company’s registrars, and attend the meeting in person will
also be permitted to vote.
ABOUT
XTL BIOPHARMACEUTICALS LTD.
XTL
Biopharmaceuticals Ltd. (“XTL”) is engaged in the acquisition, development and
commercialization of therapeutics for the treatment of infectious diseases,
with
a focus on hepatitis C. XTL is developing XTL-2125 - a small molecule,
non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is
currently in a Phase 1 clinical trial in patients with chronic hepatitis C.
XTL
is also developing XTL-6865 - a combination of two monoclonal antibodies against
the hepatitis C virus - presently in Phase 1 clinical trials in patients with
chronic hepatitis C. XTL’s hepatitis C pipeline also includes several families
of pre-clinical hepatitis C small molecule inhibitors. XTL also has an
active in-licensing and acquisition program designed to identify and acquire
additional drug candidates. XTL is publicly traded on the NASDAQ, London, and
Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| XTL BIOPHARMACEUTICALS LTD. | ||
| |
|
|
| Date: October 25, 2006 | By: | /s/ Bill Kessler |
|
Bill
Kessler
Director of Finance
|
||